New Improvement of PFS in First-Line Treatment of Advanced Renal-Cell Carcinoma

Data from ASCO GU23 show better improvement of progression-free survival (PFS) for advanced renal-cell carcinoma (aRRC) patients receiving cabozantinib together with nivolumab and ipilimumab, when compared to adding placebo. However, subgroup analysis suggests better outcomes for patients in intermediate IMDC risk group.